Results 1 - 10 for Xanomeline

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment ...
Am J Psychiatry 165:8, August 2008 1033 Article ajp.psychiatryonline.org This article is featured in this month's AJP Audio , is the subject of a CME course (p. 1079), and is ...
http://rrtt.ucsd.edu/xanomeline.pdf
open  pop

XANOMELINE BINDING TO AND ACTIVATION OF MUSCARINIC RECEPTORS
417 XANOMELINE BINDING TO AND ACTIVATION OF MUSCARINIC RECEPTORS J. Jakubik 1, E. Machova 1, E.E. El-Fakahany 2, V. Dolezal 1 1 Institute of Physiology CAS, v.v.i., Prague, Czech ...
http://www.kenes.com/adpd2009/cd/pdf/417.pdf
open  pop

Program#/Poster#: 532.4/D34 Title:
Program#/Poster#: 532.4/D34 Title: Effects of long-term exposure of M3 muscarinic receptors to xanomeline on receptor activation Authors: *M. NOETZEL , M. K. O. GRANT, E. E. EL ...
http://files.abstractsonline.com/SUPT/146/1981/Noetzel_532.4.pdf
open  pop

Selective Targeting of Muscarinic Receptors: Novel Therapeutic ...
Xanomeline was shown to have a statistically modest effect on cognitive function (p = 0.06). More strikingly, xanomeline exhibited robust therapeutic effects on psychotic symptoms and ...
http://bentham.org/cn/sample/cn3-1/006AC.pdf
open  pop

Practice parameter: Management of dementia (an evidence-based review)
BodickN, Offen W, Levey A, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer'sdisease.
http://www.aan.com/professionals/practice/pdfs/gl0012.pdf
open  pop

Molecule of the Month
Phase III clinical trials with Xanomeline an M1/M4 preferring orthosteric agonist, demonstrated efficacy as both a cognition enhancing agent, are more interestingly, as an ...
http://bentham.org/ctmc/molecule%20of%20Month-8-6/Molecule%20of%20Month-MS.pdf
open  pop

LETTERS TO THE EDITOR
Xanomeline also has moderate affinity for dopamine D 3 receptors. The recent discovery of highly selective allosteric potentiators of M 1 and M 4 receptors (5-7) presently allows ...
http://ajp.psychiatryonline.org/cgi/reprint/166/1/111-a.pdf
open  pop

Practice Parameter: Management of Dementia (An Evidence-Based Review)
Other muscarinic agonists, including xanomeline (32) and SB202026, (33) produced small drug-placebo differences on the ADAS-Cog but not on a global measure, which should be present to ...
http://www.aan.com/practice/guideline/index.cfm?fuseaction=home.view&guideline=216
open  pop

Mithridion Announces Phase I Study Results in Alzheimer's Disease
In preclinical laboratory tests comparing MCD-386 to a previous M1 selective agonist, xanomeline, regarded as the best first-generation drug candidate, MCD-386 was shown to be ...
http://mithridion.com/pdf/news_releases/2009/Mithridion_Phase_I_Study_Results_AD_4.7.09.pdf
open  pop

Technical Reports
However, xanomeline suffers from side effects due to activity at several off-targets (including the other mAchRs) and is susceptible to agonist liabilities (liabilities include ...
http://www.amriglobal.com/img/document_files/TR_apr08c.pdf
open  pop

Featured Results: